Treg-targeted therapy represses tumor growth by enhancing the infiltration of CD8+ cells at the site of the tumor, improving the functions of APCs and minimizing the infiltration of myeloid suppressive cells in TME (Saleh and Elkord, 2019; Saleh and Elkord, 2020b). Here, CD8A is linked to neoplasm.